Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
News|Videos|February 9, 2021
New Treatment Can Help Patients Living with Amyloid Light Chain Amyloidosis
Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic his recent CAEL-101 findings, and how it can help shape treatment for patients living with amyloid light chain amyloidosis.
Advertisement
Pharmacy Times® interviewed Jason Valent, MD, of the Cleveland Clinic his recent CAEL-101 findings, and how it can help shape treatment for patients living with amyloid light chain
The full conversation can be found in the video above.
Advertisement
Related to this article
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5